Viking Therapeutics (NASDAQ:VKTX) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.02), Bloomberg Earnings reports.
NASDAQ VKTX traded down $0.33 during mid-day trading on Friday, hitting $7.24. The stock had a trading volume of 1,603,835 shares, compared to its average volume of 2,493,284. The stock’s 50 day moving average is $8.12. Viking Therapeutics has a twelve month low of $6.97 and a twelve month high of $24.00. The company has a market capitalization of $521.63 million, a PE ratio of -18.10 and a beta of 2.30.
A number of hedge funds and other institutional investors have recently bought and sold shares of VKTX. Great West Life Assurance Co. Can acquired a new position in Viking Therapeutics in the 4th quarter valued at $53,000. Legal & General Group Plc grew its holdings in Viking Therapeutics by 38.0% in the 4th quarter. Legal & General Group Plc now owns 10,704 shares of the biotechnology company’s stock valued at $82,000 after buying an additional 2,945 shares in the last quarter. United Services Automobile Association purchased a new stake in Viking Therapeutics in the 4th quarter valued at $83,000. Barclays PLC grew its holdings in Viking Therapeutics by 114.7% in the 4th quarter. Barclays PLC now owns 11,647 shares of the biotechnology company’s stock valued at $89,000 after buying an additional 91,118 shares in the last quarter. Finally, Wedbush Securities Inc. purchased a new stake in Viking Therapeutics in the 2nd quarter valued at $97,000. 63.77% of the stock is owned by hedge funds and other institutional investors.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol.
Read More: Why are gap-down stocks important?
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.